Trial · NCT02336607
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
NCT02336607, Not applicable, Completed, AstraZeneca; results first posted 2015-03-23
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. Trials, record NCT02336607. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02336607
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
- NCT number
- NCT02336607
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 529 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Hypertension
- Interventions
- Felodipine tablet (Plendil) alone, Felodipine tablet (Plendil)+Hydrochlorothiazide, Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK), Felodipine tablets (Plendil)+Lisinopril (Zestril)
- First posted
- 2015-01-13
- Last updated
- 2015-03-23
- Results first posted
- 2015-03-23
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 14 weeks | |
| Secondary | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. |
| Secondary | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The duration of the combination therapy was 12 weeks. Blood pressure was measured at week 14 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The duration of the combination therapy was 4 weeks. Blood pressure was measured at week 6 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The duration of the combination therapy was 8 weeks. Blood pressure was measured at week 10 of the trial. |
| Secondary | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The duration of the combination therapy was 12 weeks. Blood pressure was measured at week 14 of the trial. |
| Secondary | The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The duration of the combination therapy was 12 weeks. The change of pulse wave velocity was measured at week 14 of the trial. |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 14 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | Percentage | NUMBER |
| SECONDARY | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | Percentage | NUMBER |
| SECONDARY | The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | Percentage | NUMBER |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Change From Baseline Among All Randomized Subjects After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among All Randomized Subjects After 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 4 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 8 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Magnitude of Systolic and Diastolic Blood Pressure Changes From Baseline Among the Subjects Who Reached Target at 12 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | mmHg | MEAN |
| SECONDARY | The Change of Pulse Wave Velocity at 12 Weeks Compare With Baseline Data of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | 12 weeks | The ITT population was defined as all patients who received at least one dose of study drug after randomization and had measurements of blood pressure at baseline and from at least one visit after randomization. | m/s | MEAN |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group80
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 74.1 | 95% Confidence Interval 64.5 to 83.6 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 80.5 | 95% Confidence Interval 71.7 to 89.4 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 80.2 | 95% Confidence Interval 71.8 to 88.6 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 14 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil) | NA | 95% Confidence Interval NA to NA | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 45.8 | 95% Confidence Interval 35.1 to 56.5 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 59.5 | 95% Confidence Interval 49 to 70 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 46.2 | 95% Confidence Interval 35.9 to 56.4 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 4 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil) | NA | 95% Confidence Interval NA to NA | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 78.6 | 95% Confidence Interval 69.8 to 87.3 | Percentage | |
| The Percentage of Subjects Reaching Blood Pressure Target (Defined as < 140 / 90 mmHg) After 8 Weeks of Felodipine Sustained Release in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide. | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 79 | 95% Confidence Interval 70.1 to 87.9 | Percentage |
1 to 10 of 80Source ClinicalTrials.gov
See all 80 results by groupParticipant flow24
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 85 | |
| Overall Study | STARTED | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 85 | |
| Overall Study | STARTED | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 92 | |
| Overall Study | STARTED | Felodipine Tablet (Plendil) | 267 | |
| Overall Study | Patients Included in ITT Population | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 84 | |
| Overall Study | Patients Included in ITT Population | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 84 | |
| Overall Study | Patients Included in ITT Population | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 91 | |
| Overall Study | Patients Included in ITT Population | Felodipine Tablet (Plendil) | 222 | |
| Overall Study | Patients Included in PP Population | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 78 | |
| Overall Study | Patients Included in PP Population | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 75 |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 participant flowAdverse events16
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Headache | Nervous system disorders | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 4 | 85 | |
| other | Headache | Nervous system disorders | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 5 | 85 | |
| other | Headache | Nervous system disorders | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 4 | 92 | |
| other | Headache | Nervous system disorders | Felodipine Tablet (Plendil) | 33 | 260 | |
| other | Flushing | Vascular disorders | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 7 | 85 | |
| other | Flushing | Vascular disorders | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 3 | 85 | |
| other | Flushing | Vascular disorders | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 5 | 92 | |
| other | Flushing | Vascular disorders | Felodipine Tablet (Plendil) | 13 | 260 | |
| serious | Gastrointestinal system damage | Gastrointestinal disorders | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 0 | 85 | |
| serious | Gastrointestinal system damage | Gastrointestinal disorders | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 0 | 85 |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | ||
| Total, all-cause mortality | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | ||
| Total, all-cause mortality | Felodipine Tablet (Plendil)+Hydrochlorothiazide | ||
| Total, all-cause mortality | Felodipine Tablet (Plendil) | ||
| Total, other adverse events | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 11 | 85 |
| Total, other adverse events | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 8 | 85 |
| Total, other adverse events | Felodipine Tablet (Plendil)+Hydrochlorothiazide | 9 | 92 |
| Total, other adverse events | Felodipine Tablet (Plendil) | 46 | 260 |
| Total, serious adverse events | Felodipine Tablet (Plendil)+Metoprolol Tablet (Betaloc ZOK) | 0 | 85 |
| Total, serious adverse events | Felodipine Tablets (Plendil)+Lisinopril (Zestril) | 0 | 85 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02336607
GET https://conductscience.org/api/trials/v1/NCT02336607/results?page=2